Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Susceptibility may be the key, says ViroLogic:

This article was originally published in Clinica

Executive Summary

After years spent studying HIV drug resistance, ViroLogic now believes that the opposite phenomenon, viral hypersusceptibility, may offer a way to improve treatment for HIV-infected patients. In a retrospective study of 30 treatment-experienced patients published in AIDS (June 15th), ViroLogic researchers found that the reduction in viral load following treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) was 20 times higher in patients with virus that was hypersusceptible to NNRTIs, and no resistance-related mutations, than in those with virus showing normal sensitivity to the drugs. Viral sensitivity was determined using the South San Francisco, California company's PhenoSense HIV drug resistance assay.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel